PROGRAM OVERVIEW
|
|
 |
Let's talk lipids in the Music City! Join the National Lipid Association for the Fall Clinical Lipid Update Sept. 21-23 at the Loews Vanderbilt Hotel in Nashville for another premier event packed with an incredible agenda.
Key topics include:
- Emerging Science in Clinical Lipidology
- Lipoprotein(a): The Neglected CVD Risk Factor
- Plaque Biology and Implications for Clinical Practice
Earn up to 12.5 hours of CME/CE and hear from renowned faculty while networking with some of the greatest minds in clinical lipidology. Stay at the top of your profession by registering now to attend this important event!
Edit Parent - PROGRAM (visibility Show)
AGENDA
| Friday, September 21 | ||
|---|---|---|
| 3:45-3:55PM | Chapter Presidents Welcome & Introduction | |
| Session I: Defining Targets, Goals and Thresholds for Treatment | ||
| 3:55-4:00PM | ARS Questions | |
| 4:00-4:25PM | Best Target for Treatment: What Do the Clinical Trials Show and Why Did We End Up With LDL-C? | Dean G. Karalis, MD, FNLA |
| 4:25-4:50PM | LDL-C: Are we Assessing this Right? | Seth S. Martin, MD, MHS |
| 4:50-5:15PM | LDL-C Lowering and Cardiovascular Risk Reduction in CTT: Is it Absolute, Relative or Both? | Karen E. Aspry, MD, MS, FNLA |
| 5:15-5:40PM | When to Scratch Below the Surface: Indications for Advanced Lipid Testing | Debra A. Friedrich, DNP, FNP-BC, CLS, FNLA |
| 5:40-6:00PM | ARS Questions and Q&A Panel | |
| 6:00-7:00PM | Welcome Reception in Exhibit Hall | |
| 7:00-9:00PM | CME/CE Dinner Symposium – PCSK9 Inhibitors in Practice: Real-World Challenges and Solutions | |
| Saturday, September 22 | ||
| 6:30-8:00AM | CME/CE Breakfast Symposium | |
| 7:00-7:50AM | Breakfast in Exhibit Hall | |
| 7:50-8:00AM | Housekeeping Notes & ARS Questions for Session II | |
| Session II - Back to Basics: Lifestyle Strategies in the Management of Dyslipidemia | ||
| 8:00-8:20AM | An Insider’s View of Trending Fad Diets | Karen Collins, MS, RDN, CDN, FAND |
| 8:20-8:40AM | Evidence Based Cardioprotective Dietary Patterns | Alice H. Lichtenstein, DSc, MS |
| 8:40-9:00AM | Let’s Make a Move: Physical Activity in ASCVD Risk Reduction | Debra A. Friedrich, DNP, FNP-BC, CLS, FNLA |
| 9:00-9:20AM | ARS Questions and Q&A Panel | |
| 9:20-9:50AM | Break in Exhibit Hall | |
| 9:50-10:15AM | Clinical Pearls for the Lipidologist – Sweet and Low (Risk): Managing ASCVD Risk in Diabetes John M. Stafford, MD, PhD | |
| Session III: Emerging Science in Clinical Lipidology | ||
| 10:15-10:20AM | ARS Questions | |
| 10:20-10:40AM | 2017-2018 Journal of Clinical Lipidology Year in Review: The Intersection of Science and Clinical Practice | John R. Guyton, MD, FNLA |
| 10:40-11:00AM | PCSK9 Inhibitors in Perspective: How Does the Evidence Impact Clinical Practice? | Christopher P. Cannon, MD |
| 11:00-11:20AM | PAD: An Indicator of High CVD Risk as Well as Substantial Risk Reduction Potential with Lipid Lowering Therapy | TBD |
| 11:20-11:40AM | ARS Questions and Q&A Panel | |
| 11:40-11:55AM | SELA & NELA News & Notes | |
| 11:55AM-12:55PM | Lunch in Exhibit Hall | |
| 12:55-1:20PM | Clinical Pearls for the Lipidologist – Handling the Pressure: Measuring Blood Pressure 101 for Clinicians on the Run | Jan N. Basile, MD |
| Session IV: Lipoprotein(a): The Neglected CVD Risk Factor | ||
| 1:20-1:25PM | ARS Questions | |
| 1:25-1:35PM | Case Presentation | Seth S. Martin, MD, MHS |
| 1:35-1:55PM | Lp(a) and ASCVD Risk: Indications for Testing and Family Screening | Keith C. Ferdinand, MD, FNLA |
| 1:55-2:15PM | Aortic Stenosis and Lp(a): Mechanisms and Implications | James A. Underberg, MD, MS, FNLA |
| 2:15-2:35PM | Residual ASCVD Risk and Lp(a): Therapeutic Considerations in the High-Risk Patient | Linda C. Hemphill, MD, FNLA |
| 2:35-2:55PM | ARS Questions and Q&A Panel | |
| 2:55-3:20PM | Clinical Pearls for the Lipidologist – No Drugs for Me: Dietary Supplements in ASCVD Risk Reduction | Barbara S. Wiggins, PharmD, CLS, FNLA |
| 3:20-3:35PM | Break | |
| NLA Special Session – Bridging the Gaps in Treatment of Genetic Triglyceride Disorders: A Team-Based Approach to Differential Diagnoses and Management | ||
| 3:35-3:40PM | Pre-Activity Self-Assessment of Competencies | |
| 3:40-4:10PM | Genetic Triglyceride Disorders- Overview, Mechanism of Disease and Clinical and Genetic Presentations | Daniel E. Soffer, MD, FNLA |
| 4:10-4:20PM | Patient Case Vignette: Guess the Diagnosis |
Vikesh K. Singh, MD, MSc |
| 4:20-4:55PM | Formulating a Comprehensive Management Plan | Vikesh K. Singh, MD, MSc, Daniel E. Soffer, MD, FNLA, Kellie H. McLain, ANP-BC, CLS, FNLA Lori A. Alexander, MSHS, RD, CLS, FNLA, Joseph J. Saseen, PharmD, CLS, FNLA |
| 4:55-5:05PM | Questions & Answers | |
| 5:05-5:10PM | Post-Activity Self-Assessment of Competencies | |
| 6:30PM | Foundation of the NLA Event | |
| Sunday, September 23, 2018 | ||
| 7:00-7:50AM | Breakfast | |
| 7:50-8:00AM | Housekeeping Notes & ARS Questions for Session V | |
| Session V: Complex Cases with the "Aces" | ||
| 8:00-8:07AM | Complex Case—Patient with Primary Biliary Cirrhosis, Severe Hypercholesterolemia | John R. Guyton, MD, FNLA |
| 8:07-8:25AM | Expert Panel—Differential Diagnoses and Management of Dyslipidemia in Liver Disease Including NASH, Chronic Hepatitis, Primary Biliary Cirrhosis and Lipoprotein-X | |
| 8:25-8:32AM | Complex Case—Patient with Severe Hypercholesterolemia, Tuboeruptive Xanthomas over Knees and Elbows with Palmar Xanthomas | Daniel E. Soffer, MD, FNLA |
| 8:32-8:52AM | Expert Panel—Differential Diagnoses, Genetics and Management of Familial Dysbetalipoproteinemia | |
| 8:52-9:00AM | Complex Case—Patient with Statin Intolerance, Drug-Drug Interaction Complications and is Nonadherent | Anne C. Goldberg, MD, FNLA |
| 9:00-9:20AM | Expert Panel—Management Options for Statin Intolerance and Ways to Improve Adherence | |
| 9:20-9:40AM | ARS Questions and Q&A Panel | |
| Session VI: Plaque Biology and Implications for Clinical Practice | ||
| 9:40-9:45AM | ARS Questions | |
| 9:45-10:05AM | The Pathobiology of Atherosclerosis: Understanding Calcification and Clinical Implications | Edward Fisher, MD, PhD, FNLA |
| 10:05-10:25AM | Plaque Imaging in Clinical Practice | Michael J. Blaha, MD, MPH |
| 10:25-10:45AM | Statins and Coronary Artery Calcification: Friend or Foe? | Edward Gill, MD, FNLA |
| 10:45-11:05AM | ARS Questions and Q&A Panel | |
| 11:05AM | Adjourn | |
ANCILLARY COURSES
Are you new to Lipidology or just looking to brush up on the changing information coming out in the field? Attend one of our ancillary courses taught by Experts in the area of Lipidology:
The NLA's Masters in Lipidology course provides an advanced examination of the core curriculum in Clinical Lipidology. This course is designed for any health care professional with experience in Lipidology who desires advanced training. Experts in the field of Lipidology will lecture on advanced concepts and guide participants through interactive learning scenarios that provide tools and skills to further advance personal standards of practice. It is recommended that attendees have already completed preparatory coursework (eg Foundations of Lipidology [formerly Lipid Academy] or similar core curriculum training).
The NLA's Foundations of Lipidology course, formerly Lipid Academy, provides an introductory review of the core curriculum in Clinical Lipidology. This course is designed for any healthcare professional seeking to learn the fundamentals of Lipidology. Experts in Lipidology will lecture on basic concepts and guide participants through interactive learning scenarios that provide the knowledge and tools necessary to work effectively in a lipid practice, and prepare for advanced training.
FEATURED PRESENTATIONS
PCSK9 Inhibitors in Perspective: How Does the Evidence Impact Clinical Practice?
(Part of Session II: Emerging Science in Clinical Lipidology) Saturday, September 22 - 8:20-8:40 AMThe recent approval of a new class of lipid-lowering agents – the PCSK9 inhibitors – represents a significant advance in the management of patients with dyslipidemia. But many questions remain regarding their safety, efficacy, and role in clinical practice. Dr. Cannon will aim to review the key clinical trial data for the PCSK9 inhibitors and discuss their potential role in clinical practice. He will also look at current use of lipid-lowering therapies in clinical practice and highlight opportunities to use the standard agents first (statin and ezetimibe), before moving onto PCKS9 inhibitors. Barriers to use from insurance companies are one area, but we as clinicians can provide documentation of the rationale for high risk patients; it should help target these new agents to appropriate patients in a cost-effective way.
Christopher P. Cannon, MD, Professor of Medicine, Harvard Medical School Executive Director of Cardiometabolic Trials Harvard Clinical Research Institute Senior Investigator, TIMI Study Group Cardiovascular Division Brigham and Women’s Hospital Boston, MA
ACCREDITATION INFORMATION
Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses and registered dietitians with an interest in lipid management.
Type of Activity
Live Activity
Application
Educational Objectives
At the conclusion of this activity, all participants should be able to:
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team.
Session I: Defining Targets, Goals, and Thresholds for Treatment
- Define lipid treatment goals for patients with dyslipidemia.
- Describe the various measurements of low-density lipoprotein (LDL-C) and the effect on clinical decisions.
- Review the evidence for benefit from LDL-C lowering therapies.
- Evaluate clinical scenarios where additional lipid testing may inform clinical decisions.
Session II: Back to Basics: Lifestyle Strategies in the Management of Dyslipidemia
- Outline the impact of various diets on short and long-term weight loss.
- Utilize effective diet and lifestyle strategies for dyslipidemia management.
- Assess the impact of increasing physical activity on Atherosclerotic Cardiovascular Disease (ASCVD) risk.
Clinical Pearls for the Lipidologist
- Discuss practical strategies for the optimal preventive therapy in diabetes.
- Discuss practical strategies for evaluating blood pressure in the clinic.
- Discuss practical non-prescription treatment strategies for ASCVD prevention.
Session III: Emerging Science in Clinical Lipidology
- Review the practical implications of current publications to the evaluation and management of patients with dyslipidemia.
- Assess the implications of recent ASCVD outcomes data for the clinical management of patients with dyslipidemia.
- Evaluate current and novel biomarkers and their impact on Cardiovascular (CV) risk detection and management.
Session IV: Lipoprotein(a): The Neglected CVD Risk Factor
- Review current recommendations for Lipoprotein(a) (Lp(a)) screening.
- Determine possible association between Lp(a) levels and the development of aortic stenosis.
- Define treatment options to reduce residual ASCVD risk.
NLA Special Session: Bridging the Gaps in Treatment of Genetic Triglyceride Disorders: A Team-Based Approach to Differential Diagnoses and Management
- Identify genetic triglyceride disorders, including Familial Combined Hyperlipidemia, Hypertriglyceridemia and Familial Chylomicronemia Syndrome (FCS), in clinical practice.
- Review current management recommendations and emerging therapeutic interventions for improving the outcomes in patients with FCS.
- Implement a team-based approach to the clinical management of FCS, effectively involving lipidologists, gastroenterologists, nurses, pharmacists, dietitians, lifestyle educators and other healthcare professionals.
Session V: Complex Cases with the “Aces”
- Discuss complex lipid case management for clinical lipidologists.
Session VI: Plaque Biology and Implications for Clinical Practice
- Review the pathogenesis of atherosclerotic plaque development and progression.
- Discuss the roles of imaging in cardiovascular disease risk evaluation.
- Review the atherosclerotic plague effects of various lipid treatment strategies.
Criteria for Success:
Statements of credit will be awarded based on the participant´s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme.
For Pharmacists: Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within four weeks.
Disclosure Statement:
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.
Commercial Support:
Full notification of commercial support will be provided in the activity accreditation.
.png)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.25 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 12.50 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.50 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
Pharmacist Accreditation Statement
Universal Activity Number JA0007192-0000-18-019-L01-P (Application)
This Activity has been approved for 12.50 contact hour(s) (1.250 CEUs) of the Accreditation Council for Pharmacy Education
Nursing
The maximum number of hours awarded for this CE activity is 12.4 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Foundations of Lipidology
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME.
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 13 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.
Pharmacists
Universal Activity Number – JA0007192-0000-18-017-L01-P (Application)
This Activity has been approved for 13.25 contact hour(s) (1.325 CEUs) of the Accreditation Council for Pharmacy Education.
Nursing
The maximum number of hours awarded for this CE activity is 13.3 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Masters in Lipidology
In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME.
Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 14 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.
Pharmacists
Universal Activity Number – JA0007192-0000-18-018-L01-P (Application)
This Activity has been approved for 14.75 contact hour(s) (1.475 CEUs) of the Accreditation Council for Pharmacy Education.
Nursing
The maximum number of hours awarded for this CE activity is 14.7 contact hours.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Delete PROGRAM
Edit Parent - ENGAGE (visibility Show)
SOCIAL MEDIA
#NLANashville
Be part of the conversation and get the latest news and announcements from the Fall CLU. Follow the NLA on Facebook, Twitter, LinkedIn and Instagram. Use the hashtag #NLANashville when posting about the meeting.
CONNECT WITH EXHIBITORS
Aegerion Pharmaceuticals
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes JUXTAPID® and MYALEPT®. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
www.novelion.com
Akcea Therapeutics
Akcea Therapeutics is a pharmaceutical development and commercialization company focused on helping patients living with serious cardiometabolic lipid disorders. Akcea’s pipeline includes advanced RNA-targeted antisense therapeutics being investigated to treat patients with a wide range of lipid disorders including rare hyperlipidemias, hyperlipoproteinemia(a), and hypertriglyceridemia with cardiovascular risk. Volanesorsen, Akcea's most advanced investigational drug, has completed Phase 3 trials to reduce ApoC-III protein production and to lower triglycerides to treat patients with familial chylomicronemia syndrome (FCS) and is in Phase 3 trials for patients with familial partial lipodystrophy (FPL).
www.akceatx.com
Alexion Pharmaceuticals
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases, including lysosomal acid lipase deficiency (LAL-D), through the innovation, development and commercialization of life-changing therapies.
www.alexion.com
Amarin Pharma, Inc.
Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Vascepa® (icosapent ethyl), Amarin's first FDA approved product, is a pure, EPA-only, omega-3 fatty acid product available by prescription.
www.amarincorp.com
Ambry Genetics
We believe in the power of people working together towards one goal, one purpose. And the power that lies within our walls to make a life-changing difference. We will not stop until human disease is understood.
www.ambrygen.com
Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
www.amgen.com
Boston Heart Diagnostics
Boston Heart Diagnostics recognizes that CVD and diabetes are complex and every patient’s story is different. A patient’s treatment plan needs to be individualized if we are to make a significant impact to improve health outcomes. Boston Heart is transforming the standard of care by providing tailored patient reports, which are created by integrating a patient’s test results, health history and food likes and dislikes. This comprehensive approach offers a more complete picture of a patient’s health. Boston Heart’s patient and healthcare provider portals are used to deliver these reports in a secure, protected environment. Boston Heart’s solutions are designed to engage and educate patients on the actions they can take toward achieving and maintaining a healthier lifestyle.
www.bostonheartdiagnostics.com
Kaneka Pharma America
Kowa Pharmaceuticals
Established in 2008, Kowa Pharmaceuticals America, Inc., is committed to developing and delivering safe, effective solutions in the field of cardiometabolic therapeutics. We do this by maintaining high ethical and professional standards--and it all starts with people. By empowering our employees to live this mission, we can create a healthier vision for the future.
www.kowapharma.com
Medicure Pharma, Inc.
Medicure Pharma is focused on the development and commercialization of a growing portfolio of cardiovascular therapeutics for the U.S. market. We have an unwavering focus on delivering safe, efficacious and cost-effective medicines that benefit patients and healthcare providers.
www.medicure.com
Quest Diagnostics
Quest Diagnostics, the world’s leading provider of diagnostic testing, information and services, offers the Cardio IQ Solution—a comprehensive approach to heart health.
www.questdiagnostics.com
Retrophin Inc.
Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.
www.retrophin.com
Sanofi-Regeneron
Sanofi, a global healthcare leader, discovers, develops, and distributes therapeutic solutions focused on patients’ needs. Regeneron, a leading biopharmaceutical company, discovers, develops, manufactures, and commercializes biologic medicines for serious medical conditions. Since 2007, Sanofi and Regeneron have collaborated to develop and commercialize fully human monoclonal antibodies utilizing proprietary technologies.
www.sanofi-us
VAP Diagnostics
VAP Diagnostics Lab is a clinical reference laboratory specializing in cardiometabolic testing and disease management. VAP Diagnostics provides clinicians with a single source for the proprietary VAP+® Test and other standard and specialty cardiometabolic tests, as well as customizable disease state panels. Using direct (not estimated) measurement, VAP+ identifies cholesterol, triglyceride and genetic lipid disorders, enabling health care professionals to accurately stratify cardiovascular risk and recommend personalized treatment strategies to improve health outcomes. Vertical Auto Profile (VAP+) technology reveals residual cardiometabolic risk as recommended in the NCEP ATP III, ADA/ACC Joint Consensus and AACE guidelines
www.vapdiagnostics.com
Delete ENGAGE
Edit Parent - VENUE (visibility Show)
HOTEL INFORMATION
Loews Vanderbilt Hotel
2100 West End Avenue
Nashville, TN
Meeting Room Rate: $225/night plus tax
Room Reservation Cut-Off-Date: August 20, 2018
For reservations, click here or call (800) 235-6397 and ask for the National Lipid Association room block. Experience Southern hospitality in the Music City at the Loews Vanderbilt which offers premier dining and is just one mile from Music Row!
More about the venueVISIT NASHVILLE
Nothing says “Nashville" like a night at the Grand Ole Opry. What began as a simple radio broadcast in 1925 is today an entertainment phenomenon showcasing a mix of country music greats-- new stars, superstars, and legends. Among the Opry's current members are Dierks Bentley, Charlie Daniels, Vince Gill, Loretta Lynn, Martina McBride, Brad Paisley, Carrie Underwood, and Keith Urban. Known around the world as "the show that made country music famous," you can count on things happening at the Opry that you just can't see anywhere else. Take in a show or do a backstage tour!
Country Music Hall of Fame and Museum
The Country Music Hall of Fame® and Museum is the definitive home of America’s music, safeguarding more than 2.5 million priceless artifacts, including countless recordings and photographs, numerous stage costumes, musical instruments, and more.
The world’s only full-scale reproduction of the famous Greek temple, Nashville's Parthenon stands in Centennial Park and features both the city’s art museum and Athena Parthenos. At almost 42 feet in height, Athena Parthenos is the tallest indoor sculpture in the Western world.
Delete VENUE
Edit Parent - SUPPORT (visibility Show)
EXHIBIT IN NASHVILLE
It is our pleasure to invite you to join us as an exhibitor at our 2018 Clinical Lipid Updates. NLA meetings provide you with an opportunity to reach your target audience of Lipidologists, Cardiologists, Endocrinologists, Primary Care Physicians, PhD researchers, and clinical team affiliates, from an array of disciplines including nurses, nurse practitioners, physician assistants, pharmacists, exercise physiologists, and dietitians, in a uniquely intimate educational setting. We are proud to showcase not only an agenda led by distinguished faculty who are leaders in their fields, but a lively exhibit hall to act as a home-base for our attendees. On behalf of our board of directors and the members we serve, we look forward to seeing you in 2018.
HOST AN EXPERT THEATRE
National Lipid Association attendees are passionate healthcare providers who expect high-quality and innovative education while attending the Clinical Lipid Update. Add your presentation to their list of must-see events by signing up to host an Expert Theater in 2018.
HOST A SYMPOSIUM
The NLA has established that independently developed CME/CE-certified satellite symposia held in conjunction with the scientific meetings of the NLA are valuable opportunities to provide continuing education for our members and meeting participants.
In this regard, we are pleased to offer satellite symposia opportunities in conjunction with our 2018 Spring Clinical Lipid Update. Satellite symposia curriculum should include educational topics that complement or supplement the Spring CLU program agenda, addressing educational gaps preventing optimal patient care. Download our guidelines to view important information regarding hosting a satellite symposium, including the proposal creation and application processes.
Please contact the NLA Program Development department directly should you have any questions or require additional information. We hope to see you in San Antonio!
Interested in non-CME programming? Please email exhibits@lipid.org
Delete SUPPORT
Edit Parent - SPECIAL EVENTS (visibility Show)
SYMPOSIA
CME/CE Dinner Symposium – PCSK9 Inhibitors in Practice: Real-World Challenges and Solutions
Friday, September 21
7:00-9:00pm
Location: Carmichael/McTyeire
This activity delves into the treatment advances and clinical considerations in lowering cardiovascular risk through an interactive “Do It Better” activity. Clinical scenarios on the management of hypercholesterolemia will be presented for recognition of suboptimal treatment approaches, followed by faculty discussion. The chance to apply key learnings will then be provided via audience response to multi-faceted management options in a similar clinical scenario. The session will cover important information, such as latest clinical trial data on PCSK9 inhibitors, optimal LCL-C goals, appropriate patients for nonstatin lipid-lowering therapy, common reasons for PCSK9 inhibitor denial, and team-based approaches to improve patient access.
Hosted by Horizon CME and RealCME.
This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
FOUNDATION EVENT
Put your trivia skills to the test at the Foundation of the NLA’s Fall CLU event!
Join a team of your peers and put your heads together to compete for prizes! Your quizmaster will cover a variety of categories including pop-culture, music, NLA history, and more. Held at the Fall CLU host hotel, enjoy food and drink with a side of friendly competition.
Purchase Your Ticket!
Saturday, September 22
6:30 – 8:30 PM
$75.00 Per Person
Delete SPECIAL EVENTS
Register for 2018 Fall Clinical Lipid Update
Disclaimer
Registration: Online registration and payment must be received no later than September 20, 2018. After this date, meeting materials and name badge cannot be guaranteed, but onsite registration will be available until September 23, 2018. By registering for this meeting, attendee understands and agrees that attendee’s name, city, and state may be shared with other attendees and exhibitors. By allowing an exhibitor to scan the conference badge, attendee understands, agrees and consents to the sharing of attendee’s contact information with the company that scanned the conference badge.
Cancellation: Telephone cancellations will not be accepted. A written notice of cancellation must be received no later than August 21, 2018. This includes social events and guest fees. There will be a $100 fee for all cancellations. There will be no refunds if cancelling within 30 days of the start of the meeting date.
Attendees who need special reasonable accommodations or who have special needs should contact the meeting organizers at 904-998-0854.